Lafutidine free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319528

CAS#: 118288-08-7 (free base)

Description: Lafutidine is a second generation histamine H2 receptor antagonist having multimodal mechanism of action and used to treat gastrointestinal disorders. It is marketed in Japan and India. Like other H2 receptor antagonists it prevents the secretion of gastric acid. It also activates calcitonin gene related peptide, resulting in the stimulation of nitric oxide (NO) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of H. pylori to gastric cells.


Chemical Structure

img
Lafutidine free base
CAS# 118288-08-7 (free base)

Theoretical Analysis

MedKoo Cat#: 319528
Name: Lafutidine free base
CAS#: 118288-08-7 (free base)
Chemical Formula: C22H29N3O4S
Exact Mass: 431.18788
Molecular Weight: 431.55
Elemental Analysis: C, 61.23; H, 6.77; N, 9.74; O, 14.83; S, 7.43

Size Price Shipping out time Quantity
1g USD 250 2 Weeks
2g USD 450 2 Weeks
5g USD 750 2 Weeks
10g USD 1250 2 Weeks
20g USD 2250 2 Weeks
50g USD 3950 2 Weeks
100g USD 5450 2 Weeks
200g USD 8450 2 Weeks
500g USD 14650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-28. Prices are subject to change without notice.

Lafutidine free base, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Related CAS #: 118288-08-7 (free base)   169899-19-8   206449-93-6    

Synonym: FRG-8813; FRG8813; FRG 8813; Lafutidine; trade name: Protecadin; Stogar.

IUPAC/Chemical Name: 2-(furan-2-ylmethylsulfinyl)-N-[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide

InChi Key: KMZQAVXSMUKBPD-DJWKRKHSSA-N

InChi Code: InChI=1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2-

SMILES Code: O=C(NC/C=C\COC1=NC=CC(CN2CCCCC2)=C1)CS(CC3=CC=CO3)=O

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 431.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kim EH, Lee YC, Chang YW, Park JJ, Chun HJ, Jung HY, Kim HS, Jeong HY, Seol SY, Han SW, Choi MG, Park SH, Lee OJ, Jung JT, Lee DH, Jung HC, Lee ST, Kim JG, Youn SJ, Kim HY, Lee SW. Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial. Dig Dis Sci. 2015 Jun;60(6):1724-32. doi: 10.1007/s10620-014-3489-4. Epub 2014 Dec 23. PubMed PMID: 25532503.

2: Namikawa T, Munekage E, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Anticancer Res. 2014 Dec;34(12):7297-301. PubMed PMID: 25503163.

3: Maity S, Choudhury S, Hazra A, Das AK. Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia. Indian J Pharmacol. 2014 Sep-Oct;46(5):498-502. doi: 10.4103/0253-7613.140580. PubMed PMID: 25298578; PubMed Central PMCID: PMC4175885.

4: Patil S, Talele GS. Gastroretentive mucoadhesive tablet of lafutidine for controlled release and enhanced bioavailability. Drug Deliv. 2015 May;22(3):312-9. doi: 10.3109/10717544.2013.877099. Epub 2014 Jan 29. PubMed PMID: 24471787.

5: Tsukaguchi M, Shibano M, Matsuura A, Mukai S. The protective effects of lafutidine for bortezomib induced peripheral neuropathy. J Blood Med. 2013 Jul 11;4:81-5. doi: 10.2147/JBM.S44127. Print 2013. PubMed PMID: 23874126; PubMed Central PMCID: PMC3712744.

6: Ogawa Y, Ichinokawa Y, Hiruma M, Machida Y, Funakushi N, Sadamasa H, Hiruma M. Retrospective cohort study on combination therapy with the histamine H2-receptor antagonist lafutidine for antihistamine-resistant chronic urticaria. J Dermatolog Treat. 2013 Dec;24(6):463-5. doi: 10.3109/09546634.2013.800183. Epub 2013 May 21. PubMed PMID: 23639034.

7: Nakano M, Ajioka H, Abe M, Kiniwa M. Possible involvement of host defense mechanism in the suppression of rat acute reflux esophagitis by the particular histamine H2 receptor antagonist lafutidine. Pharmacology. 2012;90(3-4):205-11. doi: 10.1159/000342386. Epub 2012 Sep 13. PubMed PMID: 23038658.

8: Murata T, Kawashima M, Terayama Y. [Case report: patient with central nervous system side effects due to lafutidine]. Nihon Naika Gakkai Zasshi. 2012 Jul 10;101(7):2048-50. Japanese. PubMed PMID: 22897010.

9: Kudo T, Fujinami H, Ando T, Nishikawa J, Ogawa K, Hosokawa A, Orihara T, Murakami J, Takahara T, Sugiyama T. Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study. Helicobacter. 2012 Aug;17(4):277-81. doi: 10.1111/j.1523-5378.2012.00943.x. Epub 2012 Mar 20. PubMed PMID: 22759327.

10: Nagano H, Sanai H, Muraoka M, Takagi K. Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies. Gynecol Oncol. 2012 Oct;127(1):172-4. doi: 10.1016/j.ygyno.2012.06.029. Epub 2012 Jun 26. PubMed PMID: 22750259.

11: Jadhav K, Dhamecha D, Tate A, Tambe H, Patil MB. Application of UV spectrophotometric method for easy and rapid estimation of lafutidine in bulk and pharmaceutical formulation. Pharm Methods. 2011 Oct;2(4):264-7. doi: 10.4103/2229-4708.93398. PubMed PMID: 23781468; PubMed Central PMCID: PMC3658075.

12: Dewan B, Philipose N. Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial. Gastroenterol Res Pract. 2011;2011:640685. doi: 10.1155/2011/640685. Epub 2011 May 5. PubMed PMID: 21687618; PubMed Central PMCID: PMC3113257.

13: Dewan B, Chimata R. An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition. World J Gastrointest Pharmacol Ther. 2010 Oct 6;1(5):112-8. doi: 10.4292/wjgpt.v1.i5.112. PubMed PMID: 21577305; PubMed Central PMCID: PMC3091155.

14: Iida H, Inamori M, Uchiyama T, Endo H, Hosono K, Akiyama T, Sakamoto Y, Fujita K, Takahashi H, Yoneda M, Koide T, Tokoro C, Goto A, Abe Y, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. Early effects of oral administration of lafutidine with peppermint oil, compared with lafutidine alone, on intragastric pH values. Hepatogastroenterology. 2011 Jan-Feb;58(105):235-8. PubMed PMID: 21510321.

15: Inamori M, Iida H, Hosono K, Endo H, Sakamoto Y, Takahashi H, Koide T, Tokoro C, Goto A, Abe Y, Hiratsuka N, Nakajima A, Fujita M. The histamine H2 receptor antagonist lafutidine in Japanese patients with non-erosive reflux disease. Hepatogastroenterology. 2010 Nov-Dec;57(104):1430-4. PubMed PMID: 21443098.

16: Ren Q, Ma B, Yang K, Yan X. Lafutidine-based triple therapy for Helicobacter pylori eradication. Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1074-81. PubMed PMID: 21410034.

17: Nakano M, Kitano S, Nanri M, Kiniwa M. Lafutidine, a unique histamine H2-receptor antagonist, inhibits distention-induced gastric acid secretion through an H2 receptor-independent mechanism. Eur J Pharmacol. 2011 May 11;658(2-3):236-41. doi: 10.1016/j.ejphar.2011.02.007. Epub 2011 Feb 22. PubMed PMID: 21349265.

18: Ohya TR, Endo H, Kawagoe K, Yanagawa T, Hanawa K, Ohata K, Asayama M, Hisatomi K, Teratani T, Gunji T, Sato H, Matsuhashi N. A prospective randomized trial of lafutidine vs rabeprazole on post-ESD gastric ulcers. World J Gastrointest Endosc. 2010 Jan 16;2(1):36-40. doi: 10.4253/wjge.v2.i1.36. PubMed PMID: 21160677; PubMed Central PMCID: PMC2998864.

19: Kato M, Kamada G, Yamamoto K, Nishida U, Imai A, Yoshida T, Ono S, Nakagawa M, Nakagawa S, Shimizu Y, Asaka M. Lafutidine prevents low-dose aspirin and loxoprofen induced gastric injury: a randomized, double-blinded, placebo controlled study. J Gastroenterol Hepatol. 2010 Oct;25(10):1631-5. doi: 10.1111/j.1440-1746.2010.06375.x. PubMed PMID: 20880171.

20: Akiba Y, Kaunitz JD. Lafutidine, a protective H₂ receptor antagonist, enhances mucosal defense in rat esophagus. Dig Dis Sci. 2010 Nov;55(11):3063-9. doi: 10.1007/s10620-010-1379-y. Epub 2010 Sep 8. PubMed PMID: 20824506; PubMed Central PMCID: PMC2958262.